Trial Profile
Phase I Study to Evaluate Cellular Immunotherapy Using Memory-Enriched T Cells Lentivirally Transduced to Express a CD19-Specific, Hinge-Optimized, CD28-Costimulatory Chimeric Receptor and a Truncated EGFR Following Lymphodepleting Chemotherapy in Adult Patients With High-Risk CD19+ Acute Lymphoblastic Leukemia
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Dec 2023
Price :
$35
*
At a glance
- Drugs Axicabtagene ciloleucel (Primary)
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Therapeutic Use
- 28 Nov 2023 Planned End Date changed from 30 Sep 2023 to 24 Sep 2024.
- 28 Nov 2023 Planned primary completion date changed from 30 Sep 2023 to 24 Sep 2024.
- 13 Dec 2022 Status changed from active, no longer recruiting to completed as per results presented at the 64th American Society of Hematology Annual Meeting and Exposition